Browsing by Author "Sarikavak, T"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Psychotic disorder secondary to systemic corticosteroids
    Çökmüs, FP; Asçibasi, K; Sarikavak, T; Özmen, E
    The discovery of corticosteroids in 1949, revolutionized the practise of medicine. Corticosteroids become the mainstay of therapy for a variety of acute and chronic diseases (e.g., endocrinopathies, cancer, inflammatory diseases, systemical lupus erythematosus, multiple sklerosis, and asthma). Corticosteroids often induce psychiatric syndromes, including depression, mania, psychosis, delirium, obsessive-compulsive symptoms, suicidality, catatonia and reversible dementia(1). In our case, we will discuss 67 years old male patient who developed psychotic disorder after receiving systemic corticosteroid treatment.
  • No Thumbnail Available
    Item
    \ Reliability and validity of Turkish Form of Somatic Symptom Scale and Level 2 Somatic Symptom Scale
    Sarikavak, T; Balikçi, K; Aydemir, Ö
    This study is to demonstrate the reliability and validity of the Turkish form of Somatic Symptom Scale and Level 2 Somatic Symptom Scale developed according to DSM-5 criteria. Methods: This study was carried out with patients with a diagnosis of any somatic symptom disorder according to DSM-5 criteria who are under treatment in Celal Bayar University Faculty of Medicine Psychiatry Inpatient or Outpatient Clinics. Patients with any mental disease according to DSM-5 criteria except for somatic symptom disorders and patients who have physical or neurological disease requiring continuous treatment were excluded. Accordingly, 31 patient with somatic symptom disorder, 16 patients with illness anxiety disorder and three patients with conversion disorder were included. As the healthy control group 100 volunteers without any mental or physical disease were included. Beside Somatic Symptom Scale and Level 2 Somatic Symptom Scale, the most widely used self-rated scale, Health Anxiety Inven-tory (HAI) was used for concurrent validity. In reliability analysis internal consistency coefficient and item-total correlation analysis; in validity analyses factor analysis and correlation analysis with the Pearson Correlation Analysis (PCA) was performed. ROC analysis was conducted to determine sensitivity and specificity of the scale and area under the curve above 0.90 is considered as statistically significant. Results: The mean age of the study group was 29.0 +/- 11.9 years and 61.3% of the sample group (n= 92) were female. 63.3% of the group were college graduates, 19.3% primary school graduates, 10.7% is also high school graduates. Disease duration of patient group was 17.4 +/- 11.8 years. The internal consistency of the Level 2 Somatic Symptom Scale was 0.83 and, item-total correlation coefficients of the Level 2 Somatic Symptom Scale were between 0.26 and 0.62. The internal consistency of the Somatic Symptom Scale was 0.96 and, item-total correlation coefficients of the Somatic Symptom Scale were between 0.89 and 0.92. In the exploratory factor analysis of Level 2 Somatic Symptom Scale, single-factor solution was obtained and the eigenvalue was 4.67, explaining 31.16% of the total variance. Factor loadings of the items were between 0.41 and 0.78. Coefficient of correlation analysis with HAI was calculated as r=0.59. Coefficient of correlation analysis of Somatic Symptom Scale with HAI was calculated as r=0.83. According to ROC analysis, the area under the curve was found as 0.92 for Level 2 Somatic Symptom Scale, and 0.98 for Somatic Symptom Scale. Conclusion: These findings have been shown that the Somatic Symptom Scale and Level 2 Somatic Symptom Scale are reliable and valid for Turkish.
  • No Thumbnail Available
    Item
    Reliability and Validity of Turkish version of DSM-5 Substance Use Scale
    Alçi, D; Sarikavak, T; Evren, C; Karabulut, V; Çetin, T; Aydemir, Ö
    Objective: This study aims to evaluate the severity of substance use disorders according to the DSM-5 criteria and to show the reliability and validity of the Turkish version of the DSM-5 Substance Use Scale that improved to learn what kind of substances are used. Methods: In this study,54 in or out-patients who met the criteria for any substance use disorder according to DSM-5 and who are receiving treatment in Psychiatry Department of Celal Bayar University Faculty of Medicine and AMATEM department of Bak & imath;rkoy Prof. Dr. Mahzar Osman Mental Health and Neurology Training and Research Hospital, were included. One hundred volunteers without any mental or physical disease were also recruited as the control group. Beside the DSM-5 Level 2 substance use scale, Addiction Profile & Idot;ndex was used for concurrent validity. Internal consistency coefficient and item-total correlation analysis were performed for reliability analysis. ROC Analysis was used in the validity analysis. Results: Mean age was 26.97 +/- 10.20 years in the study group and 39% of the sample (n=60) were female. 5.6% (n=3) of the patient group were female and 94.4% (n=51) were male. In the control group, 57% (n=57) were female and 43% (n=43) were male. Of the patients diagnosed with substance use disorder (n=54), 88.7% had opiate use disorder, 5.6% had polysubstance use disorder, 5.6% had other (unknown) substance (synthetic cannabinoid) use disorder and 1.8% of patients have cannabis use disorder. The internal consistency of the substance use scale was 0.80 and item-total correlation coefficients were between 0,196- 0,643 (p<0.0001). Coefficient of correlation analysis with API was calculated as r=0.806 (p<0.0001). Conclusion: The results showed that DSM-5 Substance Use Scale is a valid and reliable questionnaire that can be used to measure the progress of different dimensions of alcohol and substance use.